After Sarepta’s (SRPT) manufacturing partner Catalent (CTLT) announced productivity issues with the company’s gene manufacturing sites, including its facility in Maryland, RBC Capital analyst Brian Abrahams says the firm believes weakness in shares of Sarepta today reflects "some of the potential uncertainty this may introduce." However, there are signals that "this should not be a major commercial launch issue," and the firm continues to see a buying opportunity into the upcoming SRP-9001 AdCom that it sees being "likely positive" and "a tailwind to a potential FDA accelerated approval of ‘9001 in late May." The firm keeps an Outperform rating and $200 price target on Sarepta shares.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on SRPT:
- Sarepta sees no impact on SRP-9001 from Catalent update, says BofA
- Morgan Stanley still expects Sarepta to get approval for SRP-9001
- Sarepta approval still likely despite STAT article, says William Blair
- Wave Life selloff on Sarepta article ‘makes no sense,’ says Mizuho
- Opco says buy Sarepta on selloff, views unchanged after article
